Log in
NYSEAMERICAN:VNRX

VolitionRX Stock Forecast, Price & News

$3.11
-0.10 (-3.12 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.11
Now: $3.11
$3.32
50-Day Range N/A
52-Week Range
$2.22
Now: $3.11
$6.84
Volume496,846 shs
Average Volume325,322 shs
Market Capitalization$149.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Read More
VolitionRX logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
CIKN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$149.03 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$3.11
-0.10 (-3.12 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of VolitionRX?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VolitionRX
.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for VolitionRX
.

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Thursday, August, 13th. The medical research company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The medical research company earned $0.01 million during the quarter.
View VolitionRX's earnings history
.

What price target have analysts set for VNRX?

3 analysts have issued twelve-month price objectives for VolitionRX's stock. Their forecasts range from $7.00 to $8.00. On average, they expect VolitionRX's stock price to reach $7.67 in the next year. This suggests a possible upside of 146.5% from the stock's current price.
View analysts' price targets for VolitionRX
.

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Who are VolitionRX's key executives?

VolitionRX's management team includes the following people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

Who are VolitionRX's major shareholders?

VolitionRX's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nuveen Asset Management LLC (0.29%), Bridgeway Capital Management Inc. (0.21%), Bank of New York Mellon Corp (0.19%), Charles Schwab Investment Management Inc. (0.14%), Goldman Sachs Group Inc. (0.14%) and Ovata Capital Management Ltd (0.12%). Company insiders that own VolitionRX stock include Cameron John Reynolds, Corp Ltd Eight, Jason Bradley Md Terrell and Martin Charles Faulkes.
View institutional ownership trends for VolitionRX
.

Which institutional investors are selling VolitionRX stock?

VNRX stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Advisor Group Holdings Inc., and Bank of America Corp DE. Company insiders that have sold VolitionRX company stock in the last year include Corp Ltd Eight, Jason Bradley Md Terrell, and Martin Charles Faulkes.
View insider buying and selling activity for VolitionRX
.

Which institutional investors are buying VolitionRX stock?

VNRX stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Ovata Capital Management Ltd, New York State Common Retirement Fund, Two Sigma Advisers LP, Jane Street Group LLC, and American International Group Inc.. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, Corp Ltd Eight, and Martin Charles Faulkes.
View insider buying and selling activity for VolitionRX
.

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.11.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $149.03 million. VolitionRX employs 44 workers across the globe.

What is VolitionRX's official website?

The official website for VolitionRX is www.volitionrx.com.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.